Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 10.9B 9.73B 9.06B 8.24B 15.55B 1,055B 15.62B 109B 42.7B 538B 40.93B 40.03B 1,726B P/E 2026 *
-75x
P/E 2027 * 87x
Enterprise Value 10.37B 9.27B 8.62B 7.84B 14.8B 1,004B 14.87B 104B 40.65B 512B 38.96B 38.11B 1,643B EV / Sales 2026 *
6.79x
EV / Sales 2027 * 4.68x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.08%
1 week-5.54%
Current month-6.39%
1 month-11.51%
3 months-12.10%
6 months-9.21%
Current year-18.99%
1 week 466.06
Extreme 466.06
505
1 month 466.06
Extreme 466.06
541.34
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 13.09
Extreme 13.0886
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 A Sell

Chief Executive Officer

-5,221 0.0226%
8/17/26 A Sell

General Counsel

-664 0.0029%
8/15/26 A Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%-5.54%+9.81%+215.74% 10.9B
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.64%-2.94%+45.64%+121.46% 38.75B
Weighted average by Cap. +0.51%-3.02%+50.18%+118.39%

Financials

2026 *2027 *
Net sales 1.53B 1.36B 1.27B 1.15B 2.18B 148B 2.19B 15.27B 5.98B 75.37B 5.74B 5.61B 242B 2.13B 1.9B 1.77B 1.61B 3.04B 206B 3.05B 21.28B 8.34B 105B 7.99B 7.82B 337B
Net income -183M -163M -152M -138M -261M -17.71B -262M -1.83B -717M -9.03B -687M -672M -28.98B 179M 160M 149M 135M 255M 17.32B 256M 1.79B 701M 8.83B 672M 657M 28.33B
Net Debt -525M -468M -436M -396M -748M -50.76B -752M -5.24B -2.06B -25.88B -1.97B -1.93B -83.05B -943M -842M -784M -713M -1.35B -91.29B -1.35B -9.43B -3.7B -46.54B -3.54B -3.46B -149B
Projected Income Statement - Annual - Madrigal Pharmaceuticals, Inc.
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
09/10/26 $471.75 -1.08% 312,998
08/10/26 $476.91 -2.22% 374,368
07/10/26 $487.72 -1.76% 256,248
06/10/26 $496.45 +0.57% 330,281
05/10/26 $493.62 -1.16% 246,484
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Madrigal Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
471.75USD
Average target price
682.11USD
Spread / Average Target
+44.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Madrigal Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MDGL Stock